Is AVTX or VKTX more profitable?

Viking Therapeutics' return on equity of -94.56% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalo Therapeutics N/A -97.54% -72.42% Viking Therapeutics N/A -94.56% -82.75%

Does the media prefer AVTX or VKTX?

In the previous week, Viking Therapeutics had 30 more articles in the media than Avalo Therapeutics. MarketBeat recorded 36 mentions for Viking Therapeutics and 6 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 1.17 beat Viking Therapeutics' score of 0.65 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 14 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Positive

Is AVTX or TNGX more profitable?

Tango Therapeutics' return on equity of -41.54% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalo Therapeutics N/A -97.54% -72.42% Tango Therapeutics N/A -41.54% -33.44%

Does the media favor AVTX or TNGX?

In the previous week, Tango Therapeutics had 2 more articles in the media than Avalo Therapeutics. MarketBeat recorded 8 mentions for Tango Therapeutics and 6 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 1.17 beat Tango Therapeutics' score of 1.08 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AVTX or CPRX?

In the previous week, Avalo Therapeutics had 4 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 6 mentions for Avalo Therapeutics and 2 mentions for Catalyst Pharmaceuticals. Avalo Therapeutics' average media sentiment score of 1.17 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Catalyst Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is AVTX or DNLI more profitable?

Denali Therapeutics' return on equity of -52.20% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalo Therapeutics N/A -97.54% -72.42% Denali Therapeutics N/A -52.20% -43.86%

Does the media favor AVTX or DNLI?

In the previous week, Avalo Therapeutics had 1 more articles in the media than Denali Therapeutics. MarketBeat recorded 6 mentions for Avalo Therapeutics and 5 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.20 beat Avalo Therapeutics' score of 1.17 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AVTX or ADPT?

In the previous week, Adaptive Biotechnologies had 23 more articles in the media than Avalo Therapeutics. MarketBeat recorded 29 mentions for Adaptive Biotechnologies and 6 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 1.17 beat Adaptive Biotechnologies' score of 0.46 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 8 Very Positive mention(s) 6 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Avalo Therapeutics (AVTX) Competitors

$18.53 +0.48 (+2.66%)

Closing price 04:00 PM Eastern

Extended Trading

$18.54 +0.00 (+0.03%)

As of 04:10 PM Eastern

Compare

AVTX vs. VKTX, TNGX, CPRX, DNLI, and ADPT

Should you buy Avalo Therapeutics stock or one of its competitors? MarketBeat compares Avalo Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Avalo Therapeutics include Viking Therapeutics (VKTX), Tango Therapeutics (TNGX), Catalyst Pharmaceuticals (CPRX), Denali Therapeutics (DNLI), and Adaptive Biotechnologies (ADPT).

How does Avalo Therapeutics compare to Viking Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

In the previous week, Viking Therapeutics had 30 more articles in the media than Avalo Therapeutics. MarketBeat recorded 36 mentions for Viking Therapeutics and 6 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 1.17 beat Viking Therapeutics' score of 0.65 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	14 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Positive

Viking Therapeutics' return on equity of -94.56% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-97.54%	-72.42%
Viking Therapeutics	N/A	-94.56%	-82.75%

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by insiders. Comparatively, 5.3% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Avalo Therapeutics has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

Avalo Therapeutics presently has a consensus price target of $45.80, suggesting a potential upside of 147.17%. Viking Therapeutics has a consensus price target of $97.88, suggesting a potential upside of 197.13%. Given Viking Therapeutics' higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Viking Therapeutics	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67

Avalo Therapeutics has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	16,337.28	-$78.26M	-$5.46	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

Summary

Avalo Therapeutics beats Viking Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Avalo Therapeutics compare to Tango Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

Avalo Therapeutics presently has a consensus target price of $45.80, suggesting a potential upside of 147.17%. Tango Therapeutics has a consensus target price of $42.15, suggesting a potential upside of 43.58%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Avalo Therapeutics is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Avalo Therapeutics has higher earnings, but lower revenue than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	16,337.28	-$78.26M	-$5.46	N/A
Tango Therapeutics	$62.38M	68.08	-$101.59M	-$0.83	N/A

Avalo Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

In the previous week, Tango Therapeutics had 2 more articles in the media than Avalo Therapeutics. MarketBeat recorded 8 mentions for Tango Therapeutics and 6 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 1.17 beat Tango Therapeutics' score of 1.08 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics' return on equity of -41.54% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-97.54%	-72.42%
Tango Therapeutics	N/A	-41.54%	-33.44%

Summary

Avalo Therapeutics and Tango Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Avalo Therapeutics compare to Catalyst Pharmaceuticals?

Avalo Therapeutics (NASDAQ:AVTX) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Avalo Therapeutics' net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-97.54%	-72.42%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

Avalo Therapeutics has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

Catalyst Pharmaceuticals has higher revenue and earnings than Avalo Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	16,337.28	-$78.26M	-$5.46	N/A
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10

Avalo Therapeutics presently has a consensus target price of $45.80, indicating a potential upside of 147.17%. Catalyst Pharmaceuticals has a consensus target price of $32.00, indicating a potential upside of 1.62%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Avalo Therapeutics is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by company insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Avalo Therapeutics had 4 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 6 mentions for Avalo Therapeutics and 2 mentions for Catalyst Pharmaceuticals. Avalo Therapeutics' average media sentiment score of 1.17 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Catalyst Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Catalyst Pharmaceuticals beats Avalo Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Avalo Therapeutics compare to Denali Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

Avalo Therapeutics has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	16,337.28	-$78.26M	-$5.46	N/A
Denali Therapeutics	$330.53M	11.61	-$512.54M	-$2.88	N/A

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by company insiders. Comparatively, 9.7% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Avalo Therapeutics had 1 more articles in the media than Denali Therapeutics. MarketBeat recorded 6 mentions for Avalo Therapeutics and 5 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.20 beat Avalo Therapeutics' score of 1.17 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalo Therapeutics presently has a consensus target price of $45.80, suggesting a potential upside of 147.17%. Denali Therapeutics has a consensus target price of $35.17, suggesting a potential upside of 45.50%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Avalo Therapeutics is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Denali Therapeutics' return on equity of -52.20% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-97.54%	-72.42%
Denali Therapeutics	N/A	-52.20%	-43.86%

Avalo Therapeutics has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market.

Summary

Denali Therapeutics beats Avalo Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Avalo Therapeutics compare to Adaptive Biotechnologies?

Avalo Therapeutics (NASDAQ:AVTX) and Adaptive Biotechnologies (NASDAQ:ADPT) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Avalo Therapeutics currently has a consensus target price of $45.80, indicating a potential upside of 147.17%. Adaptive Biotechnologies has a consensus target price of $24.42, indicating a potential downside of 0.54%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Avalo Therapeutics is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Avalo Therapeutics has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market.

87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Adaptive Biotechnologies had 23 more articles in the media than Avalo Therapeutics. MarketBeat recorded 29 mentions for Adaptive Biotechnologies and 6 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 1.17 beat Adaptive Biotechnologies' score of 0.46 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	8 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Avalo Therapeutics has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -20.73%. Adaptive Biotechnologies' return on equity of -36.81% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-97.54%	-72.42%
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

Adaptive Biotechnologies has higher revenue and earnings than Avalo Therapeutics. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	16,337.28	-$78.26M	-$5.46	N/A
Adaptive Biotechnologies	$276.98M	14.19	-$59.50M	-$0.41	N/A

Summary

Adaptive Biotechnologies beats Avalo Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Avalo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVTX vs. The Competition

Export

Metric	Avalo Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$980.24M	$3.56B	$6.80B	$13.02B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-3.39	7.35	279.73	25.56
Price / Sales	16,337.28	1,275.27	649.61	116.36
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	4.13	17.09	11.12	6.36
Net Income	-$78.26M	-$12.52M	$3.48B	$347.58M
7 Day Performance	-5.07%	2.63%	2.67%	3.24%
1 Month Performance	-1.65%	-5.27%	-2.70%	-2.00%
1 Year Performance	106.58%	51.48%	64.43%	21.31%

Avalo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVTX Avalo Therapeutics	3.1885 of 5 stars	$18.53 +2.7%	$45.80 +147.2%	+128.8%	$980.24M	$60K	N/A	40	Positive News Upcoming Earnings
VKTX Viking Therapeutics	3.4384 of 5 stars	$33.86 -2.9%	$97.00 +186.5%	-0.2%	$4.05B	N/A	N/A	20	Earnings Report Analyst Revision
TNGX Tango Therapeutics	2.5796 of 5 stars	$26.65 -0.3%	$42.15 +58.2%	+316.7%	$3.86B	$62.38M	N/A	90	News Coverage Positive News High Trading Volume
CPRX Catalyst Pharmaceuticals	3.4461 of 5 stars	$31.49 flat	$32.00 +1.6%	N/A	$3.86B	$596.96M	18.10	80	Positive News Upcoming Earnings
DNLI Denali Therapeutics	2.9147 of 5 stars	$24.05 +2.0%	$35.17 +46.2%	+72.2%	$3.74B	$330.53M	N/A	430	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVTX) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avalo Therapeutics (AVTX) Competitors

AVTX vs. VKTX, TNGX, CPRX, DNLI, and ADPT

How does Avalo Therapeutics compare to Viking Therapeutics?

Summary

How does Avalo Therapeutics compare to Tango Therapeutics?

Summary

How does Avalo Therapeutics compare to Catalyst Pharmaceuticals?

Summary

How does Avalo Therapeutics compare to Denali Therapeutics?

Summary

How does Avalo Therapeutics compare to Adaptive Biotechnologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTX vs. The Competition

Avalo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avalo Therapeutics (AVTX) Competitors

AVTX vs. VKTX, TNGX, CPRX, DNLI, and ADPT

How does Avalo Therapeutics compare to Viking Therapeutics?

Does the media prefer AVTX or VKTX?

Is AVTX or VKTX more profitable?

Do insiders & institutionals have more ownership in AVTX or VKTX?

Which has more volatility and risk, AVTX or VKTX?

Do analysts recommend AVTX or VKTX?

Which has stronger valuation and earnings, AVTX or VKTX?

Summary

How does Avalo Therapeutics compare to Tango Therapeutics?

Do analysts rate AVTX or TNGX?

Do insiders and institutionals have more ownership in AVTX or TNGX?

Which has higher valuation and earnings, AVTX or TNGX?

Which has more risk and volatility, AVTX or TNGX?

Does the media favor AVTX or TNGX?

Is AVTX or TNGX more profitable?

Summary

How does Avalo Therapeutics compare to Catalyst Pharmaceuticals?

Is AVTX or CPRX more profitable?

Which has more risk and volatility, AVTX or CPRX?

Which has preferable earnings & valuation, AVTX or CPRX?

Do analysts prefer AVTX or CPRX?

Do insiders & institutionals believe in AVTX or CPRX?

Does the media favor AVTX or CPRX?

Summary

How does Avalo Therapeutics compare to Denali Therapeutics?

Which has higher earnings & valuation, AVTX or DNLI?

Do insiders and institutionals have more ownership in AVTX or DNLI?

Does the media favor AVTX or DNLI?

Do analysts recommend AVTX or DNLI?

Is AVTX or DNLI more profitable?

Which has more volatility & risk, AVTX or DNLI?

Summary

How does Avalo Therapeutics compare to Adaptive Biotechnologies?

Do analysts recommend AVTX or ADPT?

Which has more risk & volatility, AVTX or ADPT?

Do institutionals and insiders believe in AVTX or ADPT?

Does the media prefer AVTX or ADPT?

Is AVTX or ADPT more profitable?

Which has preferable valuation & earnings, AVTX or ADPT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTX vs. The Competition

Avalo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools